Page History

Review editorial changes for primary and metastatic cancer disorders.  See links in action section

Briefing Note Primary and Metastatic Member Forum March 2022 (1).pdf

Primary and Metastatic draft EAG Briefing Note v1 CMAG (1).pdf

1. Focal, non-focal (multiple)
2. Local metastases - sidedness? 
3. count of local metastases

Continue discussion:

What are we measuring when assessing "treatment effect"?  

Is this a histologic change?  Viability of tumor cells?

1. Primary site
2. Lymph node

Note: SSA wonders about property in this model

Will review model.  This observable pertains to the process of regression/change in the neoplasm after antineoplastic therapy.  So, observable could be modeled as presence of process changes.

Still a discussion.  What is being measured?  (Degree of presence of tumor). Can this be reproduced...base question is tumor there or not s/p therapy...tumor gone is best...everything else is questionable for the patient

1. How to handle patterns within histologies
   1. Lung (Lepidic, acinar)
   2. DCIS
   3. Bladder (differentiation)